NCT03926793 - Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

May 5, 2021

Study Completion Date

May 5, 2021

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

GB002

GB002 low dose or high dose for inhalation

DRUG

Placebo

Placebo for inhalation

DEVICE

Generic Dry Powder Inhaler

Generic dry powder inhaler for GB002 or Placebo delivery

Trial Locations (14)

15213

University of Pittsburgh Medical Center Montefiore University Hospital, Pittsburgh

27710

Duke Early Phase Research, Durham

29621

VitaLink Research - Anderson, Anderson

32224

Mayo Clinic Florida, Jacksonville

40202

Norton Pulmonary Specialists, Louisville

44195

Cleveland Clinic Foundation, Cleveland

55905

Mayo Clinic, Rochester

80045

University of Colorado Hospital, Aurora

92037

UCSD Medical Center, La Jolla

95817

University of California Davis Medical Center, Sacramento

06510

Yale New Haven Hospital, New Haven

02115

Brigham and Women's Hospital, Boston

G814DY

Golden Jubilee National Hospital, Glasgow

W12 0HS

Hammersmith Hospital, Imperial Healthcare NHS Trust, London

All Listed Sponsors

lead

GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

INDUSTRY